Stryker Co. (NYSE:SYK) Shares Acquired by Comgest Global Investors S.A.S.

Comgest Global Investors S.A.S. increased its holdings in Stryker Co. (NYSE:SYK) by 159.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,176 shares of the medical technology company’s stock after buying an additional 28,349 shares during the period. Comgest Global Investors S.A.S.’s holdings in Stryker were worth $16,682,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in SYK. International Assets Investment Management LLC boosted its position in shares of Stryker by 66,967.5% in the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock worth $308,433,000 after buying an additional 852,496 shares in the last quarter. 1832 Asset Management L.P. boosted its position in shares of Stryker by 146.9% in the 1st quarter. 1832 Asset Management L.P. now owns 878,669 shares of the medical technology company’s stock worth $314,449,000 after buying an additional 522,817 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Stryker by 287.6% in the 2nd quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company’s stock worth $172,033,000 after buying an additional 375,166 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in shares of Stryker by 49.8% in the 2nd quarter. Canada Pension Plan Investment Board now owns 686,416 shares of the medical technology company’s stock worth $233,553,000 after buying an additional 228,139 shares in the last quarter. Finally, Sofinnova Investments Inc. purchased a new stake in shares of Stryker in the 2nd quarter worth about $65,697,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SYK has been the topic of a number of recent research reports. Stifel Nicolaus reduced their target price on shares of Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Piper Sandler restated an “overweight” rating and issued a $420.00 target price (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Robert W. Baird upped their target price on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. upped their target price on shares of Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Finally, Barclays upped their target price on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Trading Up 1.8 %

SYK traded up $6.80 on Friday, reaching $390.08. 2,874,077 shares of the company’s stock were exchanged, compared to its average volume of 1,335,082. The company’s 50 day moving average is $364.07 and its 200-day moving average is $347.33. The company has a market cap of $148.71 billion, a price-to-earnings ratio of 41.81, a PEG ratio of 2.89 and a beta of 0.91. Stryker Co. has a twelve month low of $282.35 and a twelve month high of $392.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter last year, the company earned $2.46 earnings per share. Stryker’s revenue for the quarter was up 11.9% on a year-over-year basis. Equities analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares in the company, valued at approximately $3,219,495. This represents a 6.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the transaction, the vice president now owns 10,042 shares of the company’s stock, valued at approximately $3,715,540. This trade represents a 17.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock valued at $24,825,275 over the last 90 days. 5.90% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.